You just read:

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

News provided by

Protagonist Therapeutics, Inc.

May 07, 2020, 16:30 ET